Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telithromycin in CAP (High Resistance Areas)
NCT00538018Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2003
- Primary completion
- Jun 2004
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 4, randomised, open-label trial of telithromycin in community acquired pneumonia (CAP) (2 arms), sponsored by Sanofi. Primary endpoints: Total Symptoms Score of Pneumonia and Health Outcomes at End of Therapy. Started Jan 2003; status: completed.
02
Drugs
telithromycin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT00538018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00538018.